



LIFEVISION HEALTHCARE
Plot No. 138-142, EPIP, Phase-1, Jharmajri,
Baddi, Distt.: Solan (H.P.)-174103

Page
01 of 01

DEPARTMENT: QUALITY CONTROL

**CERTIFICATE OF ANALYSIS
(FINISHED PRODUCT)**

Product Name	NAUXIN		
Generic Name	Doxylamine Succinate, Pyridoxine Hydrochloride & Folic Acid Tablets		
Batch No.	LTA – 50633	A.R.No.	QC/FP/LTA – 50633
Mfg. Date	NOV. 2025	Batch Size	50,000 Tablets
Exp. Date	OCT. 2027	Sample Quantity	100 Tablets
Date of Receipt	09-11-2025	Date of Release	11-11-2025
Date of Analysis	10-11-2025	Mfg. Lic. No.	MNB/09/804 & MB/09/805
Marketed By	MYGEN PHARMA LLP		

S. No.	TEST	SPECIFICATION	OBSERVATION
1	Description	Brown coloured, oval shaped, biconvex, with break line on one side and plain on other side, film coated tablets.	Brown coloured, oval shaped, biconvex, with break line on one side and plain on other side, film coated tablets.
2	Identification Doxylamine Succinate USP Folic Acid IP Pyridoxine Hydrochloride IP	In assay by HPLC, the RT (Retention Time) of the sample solution should match with the RT of the standard solution. In assay by HPLC, the RT (Retention Time) of the sample solution should match with the RT of the standard solution. In assay by HPLC, the RT (Retention Time) of the sample solution should match with the RT of the standard solution.	In assay by HPLC, the RT (Retention Time) of the sample solution match with the RT of the standard solution. In assay by HPLC, the RT (Retention Time) of the sample solution match with the RT of the standard solution. In assay by HPLC, the RT (Retention Time) of the sample solution match with the RT of the standard solution.
3	Average weight	280 mg ± 5 %	281.65 mg
4	Uniformity of weight	± 5 % of average weight	Within the limit
5	Disintegration Test	Not more than 30 minutes	08 minutes 24 seconds
6	Physical Parameters: Length Thickness Width Hardness	11.65 mm ± 0.3 mm 4.20 mm ± 0.3 mm 7.10 mm ± 0.3 mm Not less than 4.0 Kg/cm ²	11.64 mm to 11.72 mm 4.10 mm to 4.25 mm 7.08 mm to 7.16 mm 4.5 Kg/cm ² to 5.5 Kg/cm ²
7	Assay		
	Each film coated tablet contains:		
	Doxylamine Succinate USP 20 mg	18.0 mg to 22.0 mg (90.0 % to 110.0 %)	19.938 mg (99.69 %)
	Pyridoxine Hydrochloride IP 20 mg	N.L.T. 18.0 mg (N.L.T. 90.0 %)	23.686 mg (118.43 %)
	Folic Acid IP 5 mg	N.L.T. 4.50 mg (N.L.T. 90.0 %)	5.7435 mg (114.87 %)

Remark: The above finished product complies to as per In House specification

	Analyzed by Officer-QC	Checked by Executive-QC	Approved by Manager-QC
Signature			
Date	11-11-2025	11-11-2025	11-11-2025